Pub Date : 2024-10-01Epub Date: 2021-04-15DOI: 10.18176/jiaci.0763
P Kalm-Stephens, L Nordvall, C Janson, A Malinovschi, K Alving
Background: Several studies have shown sex differences in the prevalence of asthma and an association with age. The aim of the present study was to prospectively investigate the development of asthma, wheeze, rhinitis, and allergic symptoms in adolescence and adulthood. We also aimed to determine whether sex modifies the association between baseline risk factors and incidence of asthma in early adulthood.
Methods: In the Screening Project Asthma in Schools (SPAIS) study, adolescents aged 12-15 years completed a standardized respiratory questionnaire (International Study of Asthma and Allergies in Childhood) and underwent measurements of fractional exhaled nitric oxide (FeNO) and lung function (FEV1) at baseline. Two follow-up assessments with similar questionnaires were performed after 4 and 16 years, with a total of 491 participants in all 3 examinations.
Results: The prevalence of asthma and wheeze were unchanged after 4 years but had increased after 16 years. However, the increase was significant only for females. The prevalence of rhinitis and allergy symptoms increased steadily, albeit with no differences between the sexes. The sex interaction analysis showed that higher FeNO (P=.01) and a family history of asthma (P=.02) increased the risk of incident asthma for males but not for females.
Conclusions: An increased prevalence of respiratory symptoms was seen primarily between late adolescence and young adulthood; the difference was significant for females but not for males. Allergic risk factors in early adolescence for incident asthma in early adulthood were confirmed in males but not in females. Awareness of these sex differences in the development of symptoms and of the associated risk factors is important in clinical practice.
{"title":"Sex Differences in Baseline Risk Factors for Asthma Between Early Adolescence and Young Adulthood.","authors":"P Kalm-Stephens, L Nordvall, C Janson, A Malinovschi, K Alving","doi":"10.18176/jiaci.0763","DOIUrl":"10.18176/jiaci.0763","url":null,"abstract":"<p><strong>Background: </strong>Several studies have shown sex differences in the prevalence of asthma and an association with age. The aim of the present study was to prospectively investigate the development of asthma, wheeze, rhinitis, and allergic symptoms in adolescence and adulthood. We also aimed to determine whether sex modifies the association between baseline risk factors and incidence of asthma in early adulthood.</p><p><strong>Methods: </strong>In the Screening Project Asthma in Schools (SPAIS) study, adolescents aged 12-15 years completed a standardized respiratory questionnaire (International Study of Asthma and Allergies in Childhood) and underwent measurements of fractional exhaled nitric oxide (FeNO) and lung function (FEV1) at baseline. Two follow-up assessments with similar questionnaires were performed after 4 and 16 years, with a total of 491 participants in all 3 examinations.</p><p><strong>Results: </strong>The prevalence of asthma and wheeze were unchanged after 4 years but had increased after 16 years. However, the increase was significant only for females. The prevalence of rhinitis and allergy symptoms increased steadily, albeit with no differences between the sexes. The sex interaction analysis showed that higher FeNO (P=.01) and a family history of asthma (P=.02) increased the risk of incident asthma for males but not for females.</p><p><strong>Conclusions: </strong>An increased prevalence of respiratory symptoms was seen primarily between late adolescence and young adulthood; the difference was significant for females but not for males. Allergic risk factors in early adolescence for incident asthma in early adulthood were confirmed in males but not in females. Awareness of these sex differences in the development of symptoms and of the associated risk factors is important in clinical practice.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"21-29"},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10743472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2021-04-15DOI: 10.18176/jiaci.0765
J L Izquierdo, C Almonacid, C Campos, D Morena, M Benavent, D González-de-Olano, J M Rodríguez
Objective: The objective of the present study was to determine the use of systemic corticosteroids (SCs) in patients with bronchial asthma using big data analysis.
Methods: We performed an observational, retrospective, noninterventional study based on secondary data captured from free text in the electronic health records. This study was performed based on data from the regional health service of Castille-La Mancha (SESCAM), Spain. We performed the analysis using big data and artificial intelligence via Savana® Manager version 3.0.
Results: During the study period, 103 667 patients were diagnosed with and treated for asthma at different care levels. The search was restricted to patients aged 10 to 90 years (mean age, 43.5 [95%CI, 43.4-43.7] years). Of these, 59.8% were women. SCs were taken for treatment of asthma by 58 745 patients at some point during the study period. These patients were older, with a higher prevalence of hypertension, dyslipidemia, diabetes, obesity, depression, and hiatus hernia. SCs are used frequently in the general population with asthma (31.4% in 2015 and 39.6% in 2019). SCs were prescribed mainly in primary care (59%), allergy (13%), and pulmonology (20%). The frequency of prescription of SCs had a direct impact on the main associated adverse effects.
Conclusion: In clinical practice, SCs are frequently prescribed to patients with asthma, especially in primary care. Use of SCs is associated with a greater number of adverse events. It is necessary to implement measures to reduce prescription of SCs to patients with asthma, especially in primary care.
{"title":"Systemic Corticosteroids in Patients With Bronchial Asthma: A Real-Life Study.","authors":"J L Izquierdo, C Almonacid, C Campos, D Morena, M Benavent, D González-de-Olano, J M Rodríguez","doi":"10.18176/jiaci.0765","DOIUrl":"10.18176/jiaci.0765","url":null,"abstract":"<p><strong>Objective: </strong>The objective of the present study was to determine the use of systemic corticosteroids (SCs) in patients with bronchial asthma using big data analysis.</p><p><strong>Methods: </strong>We performed an observational, retrospective, noninterventional study based on secondary data captured from free text in the electronic health records. This study was performed based on data from the regional health service of Castille-La Mancha (SESCAM), Spain. We performed the analysis using big data and artificial intelligence via Savana® Manager version 3.0.</p><p><strong>Results: </strong>During the study period, 103 667 patients were diagnosed with and treated for asthma at different care levels. The search was restricted to patients aged 10 to 90 years (mean age, 43.5 [95%CI, 43.4-43.7] years). Of these, 59.8% were women. SCs were taken for treatment of asthma by 58 745 patients at some point during the study period. These patients were older, with a higher prevalence of hypertension, dyslipidemia, diabetes, obesity, depression, and hiatus hernia. SCs are used frequently in the general population with asthma (31.4% in 2015 and 39.6% in 2019). SCs were prescribed mainly in primary care (59%), allergy (13%), and pulmonology (20%). The frequency of prescription of SCs had a direct impact on the main associated adverse effects.</p><p><strong>Conclusion: </strong>In clinical practice, SCs are frequently prescribed to patients with asthma, especially in primary care. Use of SCs is associated with a greater number of adverse events. It is necessary to implement measures to reduce prescription of SCs to patients with asthma, especially in primary care.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"30-38"},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10753210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2017-01-03DOI: 10.18176/jiaci.0137
J Azofra, S Echechipía, B Irazábal, D Muñoz, N Bernedo, B E García, G Gastaminza, M J Goikoetxea, A Joral, E Lasa, P Gamboa, C Díaz, A Beristain, D Quiñones, G Bernaola, M A Echenagusia, I Liarte, E García, J Cuesta, M D Martínez, M Velasco, N Longo, C Pastor-Vargas
Background and objective: Allergy to mollusks has been the focus of fewer studies than allergy to crustaceans. Furthermore, allergy to mollusks is less well characterized. Objectives: To describe the clinical characteristics of mollusk-allergic patients, to identify the responsible allergens, and to assess cross-reactivity.
Methods: We performed a prospective multicenter study including 45 patients with mollusk allergy, which was diagnosed based on a suggestive clinical history and a positive skin test result with the agent involved. Fractions were identified using SDS-PAGE and immunoblotting. The proteins responsible were subsequently identified using mass spectrometry. ELISA inhibition studies were performed with mollusks, dust mites, and crustaceans.
Results: We found that 25 patients (55%) were allergic to cephalopods, 14 (31%) to bivalves, and 11 (24%) to gastropods. Limpet was the third most frequent cause of allergy (15% of cases). In 31 patients (69%), the manifestation was systemic; 10 (22%) exhibited oral allergy syndrome, and 7 (15%) experienced contact urticaria. Most major allergens were found between 27 kDa and 47 kDa. ELISA inhibition assays revealed a high degree of inhibition of cephalopods and bivalves from all the groups of mollusks, mites, and crustaceans. Mass spectrometry identified tropomyosin, actin, and myosin as the major allergens.
Conclusions: Cephalopods, especially squid, are the mollusks that most frequently trigger allergic symptoms. The very frequent occurrence of allergy to limpets is striking, given their low consumption in our area. It is worth highlighting the heterogeneity observed, exemplified by the gastropods. Tropomyosin appears to be responsible for the high cross-reactivity found between mollusks, mites, and crustaceans. Three new mollusk allergens were also identified, namely, actin, enolase, and a putative C1q domain-containing protein.
{"title":"Heterogeneity in Allergy to Mollusks: A Clinical-Immunological Study in a Population From the North of Spain.","authors":"J Azofra, S Echechipía, B Irazábal, D Muñoz, N Bernedo, B E García, G Gastaminza, M J Goikoetxea, A Joral, E Lasa, P Gamboa, C Díaz, A Beristain, D Quiñones, G Bernaola, M A Echenagusia, I Liarte, E García, J Cuesta, M D Martínez, M Velasco, N Longo, C Pastor-Vargas","doi":"10.18176/jiaci.0137","DOIUrl":"10.18176/jiaci.0137","url":null,"abstract":"<p><strong>Background and objective: </strong>Allergy to mollusks has been the focus of fewer studies than allergy to crustaceans. Furthermore, allergy to mollusks is less well characterized. Objectives: To describe the clinical characteristics of mollusk-allergic patients, to identify the responsible allergens, and to assess cross-reactivity.</p><p><strong>Methods: </strong>We performed a prospective multicenter study including 45 patients with mollusk allergy, which was diagnosed based on a suggestive clinical history and a positive skin test result with the agent involved. Fractions were identified using SDS-PAGE and immunoblotting. The proteins responsible were subsequently identified using mass spectrometry. ELISA inhibition studies were performed with mollusks, dust mites, and crustaceans.</p><p><strong>Results: </strong>We found that 25 patients (55%) were allergic to cephalopods, 14 (31%) to bivalves, and 11 (24%) to gastropods. Limpet was the third most frequent cause of allergy (15% of cases). In 31 patients (69%), the manifestation was systemic; 10 (22%) exhibited oral allergy syndrome, and 7 (15%) experienced contact urticaria. Most major allergens were found between 27 kDa and 47 kDa. ELISA inhibition assays revealed a high degree of inhibition of cephalopods and bivalves from all the groups of mollusks, mites, and crustaceans. Mass spectrometry identified tropomyosin, actin, and myosin as the major allergens.</p><p><strong>Conclusions: </strong>Cephalopods, especially squid, are the mollusks that most frequently trigger allergic symptoms. The very frequent occurrence of allergy to limpets is striking, given their low consumption in our area. It is worth highlighting the heterogeneity observed, exemplified by the gastropods. Tropomyosin appears to be responsible for the high cross-reactivity found between mollusks, mites, and crustaceans. Three new mollusk allergens were also identified, namely, actin, enolase, and a putative C1q domain-containing protein.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":"1 1","pages":"252-260"},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42619489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R N Vera-Berrios, L Uriarte Vega, G Marco-Martín, M Fernández-Rivas
{"title":"Nonmandatory Labeled Legumes Are an Emergent Safety Concern: An Illustrative Case Report.","authors":"R N Vera-Berrios, L Uriarte Vega, G Marco-Martín, M Fernández-Rivas","doi":"10.18176/jiaci.1020","DOIUrl":"https://doi.org/10.18176/jiaci.1020","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":6.1,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29Epub Date: 2024-02-21DOI: 10.18176/jiaci.0974
M F Pilia, D Espejo, D Soler, X Muñoz
{"title":"Occupational Asthma Caused by Exposure to Alumina.","authors":"M F Pilia, D Espejo, D Soler, X Muñoz","doi":"10.18176/jiaci.0974","DOIUrl":"10.18176/jiaci.0974","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"270-272"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29Epub Date: 2023-12-22DOI: 10.18176/jiaci.0977
A Entrala, D Loli-Ausejo, I Losantos, R Cabañas, T Caballero
{"title":"Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH.","authors":"A Entrala, D Loli-Ausejo, I Losantos, R Cabañas, T Caballero","doi":"10.18176/jiaci.0977","DOIUrl":"10.18176/jiaci.0977","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"261-263"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29Epub Date: 2024-01-26DOI: 10.18176/jiaci.0981
M J Peñalver, S Bautista-Villanueva, R Barranco, J F Crespo, R Mielgo
{"title":"Successful Subcutaneous Desensitization to Certolizumab Pegol.","authors":"M J Peñalver, S Bautista-Villanueva, R Barranco, J F Crespo, R Mielgo","doi":"10.18176/jiaci.0981","DOIUrl":"10.18176/jiaci.0981","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"272-274"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29Epub Date: 2023-02-23DOI: 10.18176/jiaci.0899
T Mora, I Sánchez-Collado, J Mullol, R Muñoz-Cano, P Ribó, A Valero
Background: Studies on the prevalence of atopic dermatitis (AD) in adults in general populations are scarce worldwide. We performed a retrospective population-based observational cohort study of 537 098 adult patients diagnosed with AD in Catalonia, Spain, a larger population than in previous studies. Objectives: To study the prevalence of AD by age, sex, disease severity, multimorbidity, serum total immunoglobin E (tIgE), and appropriate medical treatment (AMT) for the population of Catalonia.
Methods: The study population comprised adult individuals (≥18 years) diagnosed with AD according to medical records at different health care levels (primary, hospital, emergency) in the Catalan Health System. Statistical analyses were conducted to evaluate sociodemographic characteristics, prevalence, multimorbidity, serum tIgE, and AMT.
Results: The prevalence of AD in the adult Catalan population was 8.7%, being higher for nonsevere disease (8.5%) than for severe disease (0.2%) and in females (10.1%) than in males (7.3%). Topical corticosteroids were the most prescribed drug (66.5%), and treatment was prescribed more frequently in severe AD patients, especially systemic corticosteroids (63.8%) and immunosuppressants (60.7%). More than half of severe AD patients (52.2%) had serum tIgE ≥100 kU/L, and higher values were observed for those with multimorbidity. The most frequent comorbid respiratory diseases were acute bronchitis (13.7%), allergic rhinitis (12.1%), and asthma (8.6%).
Conclusions: We provide new and robust evidence of the prevalence of AD and related characteristics in adults using a large-scale population-based study and a more significant cohort of individuals.
背景和目的:在全球范围内,有关特应性皮炎(AD)在普通人群中的成人患病率的研究很少。我们对加泰罗尼亚(西班牙)537,098 名确诊为特应性皮炎的成年患者进行了一项基于人群的回顾性队列观察研究,该研究的人群规模大于以往的研究。目的是研究按年龄、性别、疾病严重程度、多病症、血清总免疫球蛋白 E (tIgE) 和接受适当治疗 (AMT) 划分的加泰罗尼亚人群的 AD 患病率:方法:纳入加泰罗尼亚卫生系统(CHS)不同医疗保健级别(初级、医院、急诊)的医疗记录中确诊为注意力缺失症的成年人(≥18 岁)。对社会人口学特征、发病率、多病症、血清 tIgE 和 AMT 进行了统计分析:加泰罗尼亚成年人口中确诊的注意力缺失症总发病率为 8.7%,非重度人群(8.5%)高于重度人群(0.2%),女性(10.1%)高于男性(7.3%)。外用皮质类固醇激素是最常用的处方药(66.5%),在严重AD患者中,所有处方药的使用率都较高,尤其是全身性皮质类固醇激素(63.8%)和免疫抑制剂(60.7%)。半数以上(52.2%)的重症AD患者报告血清tIgE≥100 KU/L,患有多种疾病的患者血清tIgE值更高。急性支气管炎(13.7%)、过敏性鼻炎(12.1%)和哮喘(8.6%)是最常见的合并呼吸系统疾病:我们的研究通过大规模的人群研究和更重要的个体队列,为成人注意力缺失症的患病率和相关特征提供了新的有力证据。
{"title":"Prevalence of Atopic Dermatitis in the Adult Population of Catalonia, Spain: A Large-Scale, Retrospective, Population-Based Study.","authors":"T Mora, I Sánchez-Collado, J Mullol, R Muñoz-Cano, P Ribó, A Valero","doi":"10.18176/jiaci.0899","DOIUrl":"10.18176/jiaci.0899","url":null,"abstract":"<p><strong>Background: </strong>Studies on the prevalence of atopic dermatitis (AD) in adults in general populations are scarce worldwide. We performed a retrospective population-based observational cohort study of 537 098 adult patients diagnosed with AD in Catalonia, Spain, a larger population than in previous studies. Objectives: To study the prevalence of AD by age, sex, disease severity, multimorbidity, serum total immunoglobin E (tIgE), and appropriate medical treatment (AMT) for the population of Catalonia.</p><p><strong>Methods: </strong>The study population comprised adult individuals (≥18 years) diagnosed with AD according to medical records at different health care levels (primary, hospital, emergency) in the Catalan Health System. Statistical analyses were conducted to evaluate sociodemographic characteristics, prevalence, multimorbidity, serum tIgE, and AMT.</p><p><strong>Results: </strong>The prevalence of AD in the adult Catalan population was 8.7%, being higher for nonsevere disease (8.5%) than for severe disease (0.2%) and in females (10.1%) than in males (7.3%). Topical corticosteroids were the most prescribed drug (66.5%), and treatment was prescribed more frequently in severe AD patients, especially systemic corticosteroids (63.8%) and immunosuppressants (60.7%). More than half of severe AD patients (52.2%) had serum tIgE ≥100 kU/L, and higher values were observed for those with multimorbidity. The most frequent comorbid respiratory diseases were acute bronchitis (13.7%), allergic rhinitis (12.1%), and asthma (8.6%).</p><p><strong>Conclusions: </strong>We provide new and robust evidence of the prevalence of AD and related characteristics in adults using a large-scale population-based study and a more significant cohort of individuals.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"225-232"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9307308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29Epub Date: 2024-02-09DOI: 10.18176/jiaci.0975
V Plaza, J A Trigueros, J A Carretero, I Ojanguren Arranz, J M Vega Chicote, C Almonacid Sánchez, J Bartra Tomás, C Cisneros Serrano, L Domínguez Juncal, J Domínguez-Ortega, J Figueroa Rivero, J G Soto Campos, E Macías Fernández, S Martínez, J Montoro Lacomba, S Quirce
{"title":"Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force.","authors":"V Plaza, J A Trigueros, J A Carretero, I Ojanguren Arranz, J M Vega Chicote, C Almonacid Sánchez, J Bartra Tomás, C Cisneros Serrano, L Domínguez Juncal, J Domínguez-Ortega, J Figueroa Rivero, J G Soto Campos, E Macías Fernández, S Martínez, J Montoro Lacomba, S Quirce","doi":"10.18176/jiaci.0975","DOIUrl":"10.18176/jiaci.0975","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"257-260"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-29Epub Date: 2023-12-12DOI: 10.18176/jiaci.0973
G Wang, N Zhuo, Z Liu
{"title":"Off-label Use of Mepolizumab: A Potential Therapeutic Option for Eosinophilic Cystitis.","authors":"G Wang, N Zhuo, Z Liu","doi":"10.18176/jiaci.0973","DOIUrl":"10.18176/jiaci.0973","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"277-278"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}